1. Home
  2. Analysis
  3. Spironolactone
  4. Synribo

Spironolactone and Synribo drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Spironolactone (spironolactone) and Synribo (omacetaxine mepesuccinate). Common drug interactions include injection site erythema among females and nausea among males.

The phase IV clinical study analyzes what interactions people have when they take Spironolactone and Synribo. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Spironolactone?

Spironolactone has active ingredients of spironolactone. It is often used in acne. eHealthMe is studying from 122,947 Spironolactone users. Check the latest studies of Spironolactone.

What is Synribo?

Synribo has active ingredients of omacetaxine mepesuccinate. eHealthMe is studying from 799 Synribo users. Check the latest studies of Synribo.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

20 people who take Spironolactone and Synribo together, and have interactions are studied.

Spironolactone and Synribo drug interactions.

What are the common drug interactions of Spironolactone and Synribo, by gender? *:

female:

  1. Injection site erythema (redness at injection site)
  2. Nausea (feeling of having an urge to vomit)
  3. Injection site pain
  4. Malaise (a feeling of general discomfort or uneasiness)
  5. Diarrhoea
  6. Pain
  7. Haemoglobin decreased
  8. Neutropenia (an abnormally low number of neutrophils)
  9. Arthralgia (joint pain)
  10. Decreased appetite

male:

  1. Nausea (feeling of having an urge to vomit)
  2. Platelet count decreased
  3. Hypotension (abnormally low blood pressure)
  4. Injection site discolouration
  5. Injection site exfoliation (removal of the oldest dead skin from injection site)
  6. Vomiting
  7. Asthenia (weakness)
  8. Death
  9. Decreased appetite
  10. Diarrhoea

What are the common drug interactions of Spironolactone and Synribo, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Haemoglobin decreased
  2. Platelet count increased
  3. Pyrexia (fever)

10-19:

n/a

20-29:

n/a

30-39:

  1. Headache (pain in head)
  2. Injection site erythema (redness at injection site)
  3. Urine output increased

40-49:

  1. Decreased appetite
  2. Nausea (feeling of having an urge to vomit)
  3. Blood electrolytes decreased
  4. Blood magnesium decreased
  5. Blood potassium decreased
  6. Blood potassium increased
  7. Blood sodium decreased
  8. Death
  9. Dehydration (dryness resulting from the removal of water)
  10. Diarrhoea

50-59:

  1. Injection site erythema (redness at injection site)
  2. Nausea (feeling of having an urge to vomit)
  3. Injection site pain
  4. Malaise (a feeling of general discomfort or uneasiness)
  5. Activities of daily living impaired
  6. Arthralgia (joint pain)
  7. Asthenia (weakness)
  8. Constipation
  9. Decreased appetite
  10. Diarrhoea

60+:

  1. Platelet count decreased
  2. Death
  3. Vomiting
  4. Asthenia (weakness)
  5. Diarrhoea
  6. Epistaxis (bleed from the nose)
  7. Fatigue (feeling of tiredness)
  8. Hypotension (abnormally low blood pressure)
  9. Injection site discolouration
  10. Injection site exfoliation (removal of the oldest dead skin from injection site)

What are the existing conditions these people have? *

  1. Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 14 people, 70.00%
  2. High Blood Pressure: 4 people, 20.00%
  3. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 15.00%
  4. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 10.00%
  5. Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 1 person, 5.00%
  6. Pain: 1 person, 5.00%
  7. Oedema (fluid collection in tissue): 1 person, 5.00%
  8. Neuropathy Peripheral (surface nerve damage): 1 person, 5.00%
  9. Leukaemia (blood or bone marrow cancer): 1 person, 5.00%
  10. Stress And Anxiety: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Spironolactone and Synribo?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Spironolactone and Synribo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Spironolactone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Synribo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Spironolactone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Synribo and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on spironolactone and omacetaxine mepesuccinate (the active ingredients of Spironolactone and Synribo, respectively), and Spironolactone and Synribo (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.